Clinical Trials
71
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (70 trials with phase data)• Click on a phase to view related trials
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 390
- Registration Number
- NCT06931717
- Locations
- 🇦🇹
Wien AKH, Wien, Austria
🇪🇪North Estonia Medical Centre Foundation, Talinn, Estonia
🇫🇷CHU d'Angers, Angers, France
A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non-small cell lung cancer.
- Conditions
- Stage IIB-IIIB (N2) resectable non small cell lung cancer
- First Posted Date
- 2024-09-10
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 335
- Registration Number
- 2023-508773-82-00
- Locations
- 🇦🇹
Medical University Of Vienna, Vienna, Austria
🇳🇱Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Amsterdam, Netherlands
🇳🇱Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
- Conditions
- Metastatic Non Small Cell Lung CancerKRAS G12C
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Registration Number
- NCT06068153
- Locations
- 🇦🇹
Medical University of Innsbruck / UK für Innere Medizin V, Innsbruck, Austria
🇩🇪University Hospital of Munich (LMU), Department of Medicine V (Pneumology/Thoracic Oncology), Munich, Germany
🇪🇸Alicante University Dr Balmis Hospital ISABIAL, Alicante, Spain
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 220
- Registration Number
- NCT05896566
- Locations
- 🇫🇷
Gustave Roussy Cancer Center, Villejuif, France
🇩🇪HELIOS Klinikum Berlin Buch, Berlin, Germany
🇩🇪Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR, Berlin, Germany
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 44
- Registration Number
- NCT05718323
- Locations
- 🇫🇷
CHU - Angers, Angers, France
🇫🇷Centre Hospitalier d'Avignon, Avignon, France
🇫🇷Caen - CHU, Caen, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
CHOSA's Platinum Drug Response Predictor Shows Promise in Personalizing Cancer Treatment
CHOSA will release results from a blinded retrospective study predicting cisplatin efficacy in lung cancer patients from the SPLENDOUR trial by the end of Q2 2025, potentially revolutionizing treatment selection.